For example, a subpopulation of AR- and neuroendocrine (NE)-null PCa cells, termed double-null PCa (DNPC), has been observed frequently in patients treated with abiraterone, an androgen synthesis inhibitor and enzalutamide, an AR antagonist, directly contributing to the increased incidence and mortality of metastatic CRPC [47]. Here, AR is linked to posterior cortical atrophy.